Abhinav Aggarwal

Abhinav Aggarwal

Active Director Director DIN 08741927
DIN 08741927 First appointment May 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2020
Shareholding value •••• Premium profile

About Abhinav Aggarwal

Data last updated:

Abhinav Aggarwal is a Director at Dcm Pharma Private Limited (since 2020). The company operates in Pharma. Dcm Pharma Private Limited reported revenue of ₹1.07 Cr (FY 2024).

DIN 08741927
Primary Designation Director
Industry Pharma
First Appointment 13 May 2020
Oldest Company Age 6 yrs
Largest company Dcm Pharma Private Limited · ₹1.07 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Dcm Pharma Private Limited U51909CH2020PTC042985
Director13 May 20202020₹1.07 Cr (FY 2024)Active

Board colleagues of Abhinav Aggarwal

NameDINCompanyDesignation
Sumit Kumar07711843Dcm Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Dcm Pharma Private Limited
Premium access

Shareholding and investment profile for Abhinav Aggarwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abhinav Aggarwal

Abhinav Aggarwal currently holds 1 directorship: Dcm Pharma Private Limited (Director, since 13 May 2020, revenue ₹1.07 Cr (FY 2024)).

Abhinav Aggarwal was first appointed on 13 May 2020 as Director at Dcm Pharma Private Limited.

The current boards of Abhinav Aggarwal's companies include Sumit Kumar (Dcm Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available